HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Setsuya Aiba Selected Research

dabrafenib

3/2021Dabrafenib plus trametinib combination therapy triggered onset of pustulosis palmaris et plantaris in a patient with advanced cutaneous melanoma.
1/2021Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma.
11/2020Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy.
6/2020Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib.
1/2019Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy.
9/2018Two cases of dabrafenib and trametinib therapy-failed advanced melanoma successfully controlled by nivolumab monotherapy.
6/2018HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.
2/2018Severe erythema exudative multiforme developing from advanced melanoma treated with dabrafenib and trametinib followed by nivolumab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Setsuya Aiba Research Topics

Disease

49Neoplasms (Cancer)
01/2021 - 03/2004
43Melanoma (Melanoma, Malignant)
09/2021 - 07/2004
16Inflammation (Inflammations)
10/2022 - 10/2002
14Psoriasis (Pustulosis Palmaris et Plantaris)
11/2021 - 08/2002
11Mycosis Fungoides
11/2020 - 01/2006
8Atopic Dermatitis (Atopic Eczema)
01/2022 - 02/2003
8Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
02/2021 - 09/2016
8Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2020 - 09/2014
6Skin Diseases (Skin Disease)
10/2020 - 10/2002
5Autoimmune Diseases (Autoimmune Disease)
10/2022 - 09/2012
5Vitiligo
07/2021 - 10/2013
5Pemphigus (Pemphigus Vulgaris)
03/2021 - 04/2009
5Lymphoma (Lymphomas)
11/2020 - 01/2004
5Extramammary Paget Disease (Paget Disease, Extramammary)
01/2019 - 11/2012
4Bullous Pemphigoid (Pemphigoid)
11/2018 - 01/2014
4Infections
01/2018 - 08/2002
4Carcinoma (Carcinomatosis)
01/2017 - 09/2012
3Hypersensitivity (Allergy)
12/2022 - 12/2005
3Rosacea (Acne Rosacea)
05/2022 - 11/2014
3Pruritus (Itching)
09/2021 - 01/2017
3Lichen Planus (Lichen Ruber Planus)
01/2021 - 10/2002
3Eczema
01/2020 - 10/2002
3Carcinogenesis
01/2020 - 09/2018
3Acne Vulgaris
03/2019 - 09/2014
3Dermatitis
01/2019 - 10/2002
3Erythema
02/2018 - 09/2012
3Drug Eruptions (Drug Eruption)
05/2015 - 10/2003
3Contact Dermatitis (Eczema, Contact)
07/2014 - 09/2009
3Hypohidrosis
11/2013 - 01/2002
3Alopecia Areata
01/2013 - 03/2003
3Hemangiosarcoma (Angiosarcoma)
01/2013 - 01/2012
3Wounds and Injuries (Trauma)
04/2007 - 05/2005
2Systemic Lupus Erythematosus (Libman-Sacks Disease)
10/2022 - 05/2012
2Lymphomatoid Papulosis
01/2022 - 02/2018
2Localized Scleroderma (Morphea)
06/2021 - 01/2015
2Fever (Fevers)
01/2021 - 06/2020
2Necrosis
12/2020 - 04/2009
2Sarcoma (Soft Tissue Sarcoma)
09/2020 - 05/2013

Drug/Important Bio-Agent (IBA)

26NivolumabIBA
09/2021 - 06/2016
14ChemokinesIBA
03/2021 - 11/2015
13IpilimumabIBA
09/2021 - 09/2016
11Biomarkers (Surrogate Marker)IBA
01/2021 - 02/2010
10AntibodiesIBA
10/2022 - 09/2017
8Interleukin-17 (Interleukin 17)IBA
11/2021 - 09/2012
8trametinibIBA
03/2021 - 02/2018
8dabrafenibIBA
03/2021 - 02/2018
7Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
09/2021 - 09/2017
7pembrolizumabIBA
01/2021 - 01/2018
7CytokinesIBA
01/2020 - 11/2003
6Immunoglobulin E (IgE)IBA
11/2021 - 11/2005
6Therapeutic UsesIBA
01/2020 - 11/2005
6Immune Checkpoint InhibitorsIBA
01/2020 - 05/2017
6PeriostinIBA
12/2017 - 01/2015
5mogamulizumabIBA
11/2020 - 01/2018
5SteroidsIBA
10/2020 - 01/2006
5AntigensIBA
09/2020 - 08/2002
5Bexarotene (LGD1069)FDA Link
06/2020 - 01/2017
5Proteins (Proteins, Gene)FDA Link
01/2019 - 11/2005
5Adenosine Triphosphate (ATP)IBA
06/2017 - 04/2009
5HaptensIBA
06/2016 - 10/2007
4Immunoglobulin G (IgG)IBA
10/2022 - 09/2003
4Infliximab (Remicade)FDA Link
11/2021 - 07/2015
4Interleukin-23 (Interleukin 23)IBA
11/2021 - 05/2018
4Proto-Oncogene Proteins B-rafIBA
09/2021 - 01/2019
4Adrenal Cortex Hormones (Corticosteroids)IBA
07/2021 - 01/2006
4InterferonsIBA
01/2021 - 01/2006
4LigandsIBA
11/2020 - 01/2019
4EnzymesIBA
10/2020 - 04/2009
4DenosumabFDA Link
01/2020 - 01/2017
4Messenger RNA (mRNA)IBA
01/2020 - 11/2003
4Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
01/2020 - 01/2017
4RetinoidsIBA
01/2019 - 01/2004
4Interleukin-12 (IL 12)IBA
05/2018 - 02/2003
4Interferon-gamma (Interferon, gamma)IBA
09/2016 - 02/2003
3Anti-Bacterial Agents (Antibiotics)IBA
08/2023 - 01/2018
3AutoantibodiesIBA
10/2022 - 04/2009
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2021 - 04/2009
3InterleukinsIBA
11/2021 - 04/2009
3binimetinibIBA
03/2021 - 06/2020
3encorafenibIBA
03/2021 - 06/2020
3Etoposide (VP 16)FDA LinkGeneric
01/2020 - 01/2016
3Programmed Cell Death 1 ReceptorIBA
01/2019 - 01/2018
3Prednisolone (Predate)FDA LinkGeneric
11/2018 - 04/2009
3Ointments (Pastes)IBA
05/2018 - 01/2005
3RANK LigandIBA
01/2018 - 01/2016
3Matrix Metalloproteinases (MMPs)IBA
01/2018 - 11/2012
3PeplomycinIBA
01/2017 - 09/2014
2Cetuximab (Erbitux)FDA Link
12/2022 - 07/2021
2Histamine Antagonists (Antihistamines)IBA
09/2021 - 08/2003
2MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA
09/2021 - 09/2019
2MethylprednisoloneFDA LinkGeneric
07/2021 - 01/2020
2Immunoglobulins (Immunoglobulin)IBA
06/2021 - 05/2018
2Hydrocortisone (Cortisol)FDA LinkGeneric
10/2020 - 05/2011
2GlucocorticoidsIBA
10/2020 - 05/2011
2Dacarbazine (DIC)FDA LinkGeneric
09/2020 - 01/2018

Therapy/Procedure

50Therapeutics
01/2023 - 01/2006
10Immunotherapy
12/2020 - 11/2005
6Drug Therapy (Chemotherapy)
02/2021 - 09/2014
5Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
09/2021 - 05/2017
4Radiotherapy
05/2019 - 01/2012